drugset / Trial / NCT00564148

Intravitreal Avastin in Proliferative Retinopathies

NCT00564148 ↗

Phase 2 Completed 100 enrolled Ophthalmological Association Edelweiss
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study intends to assess the effect of Avastin injections in different proliferative retinopathies due to different causes

Timeline

Start
2007-07
Primary completion
2009-11
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 2.5 mg Intravitreal